How much does Pralsetinib cost for medical insurance in 2023?

Pralsetinib (Pralsetinib) is the first daily oral tyrosine kinase inhibitor for patients with non-small cell lung cancer with RET-positive metastases. It is well tolerated and demonstrates strong and durable responses in patients with RET-positive cancer regardless of tumor type. RET changes are most common in thyroid cancer, medullary thyroid carcinoma, and non-small cell lung cancer.

Among 23 patients with different types of cancer, the total effective rate was 57% and the disease control rate was 83%. These results build on previously reported positive results in RET-altered non-small cell lung cancer (NSCLC) and cancers and suggest that targeted therapies may bring unknown benefits to patients with RET fusions. RET fusion occurs when a segment of a chromosome containing the RET gene breaks off and recombines with another chromosome, producing a fusion protein that fuels cancer but is rare in many other types of tissue.

It is understood that the original drug Platinib has been marketed in China, but it has not yet entered the scope of medical insurance through the relevant regulations of the National Medical Insurance Bureau. Patients in need can only purchase it at their own expense. The price of each box of 100mg*120 tablets may be around RMB 60,000, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.